GLOBAL WHOLEHEALTH PTNRS - GWHP STOCK NEWS

Global WholeHealth Partners Corp (OTC: GWHP) provides an update on its partnership with Salud Previa in Tijuana, which specializes in various diagnostic tests including COVID-19 testing. The company highlights its extensive range of diagnostic tests, including FDA-approved products and rapid point-of-care tests. GWHP aims to enhance testing efficiency amidst the pandemic, addressing the urgent need for quick results. It maintains a focus on high-quality diagnostics and has a robust network in Mexico, positioned to meet growing healthcare demands.

Global WholeHealth Partners Corp. (OTC: GWHP) offers a wide array of COVID-19 tests, including the Antibody IgG/IgM tests that detect all identified SARS-CoV-2 strains. The company emphasizes the need for expedited testing to mitigate COVID-19 spread, utilizing advanced In-vitro Diagnostic technology and Real-Time PCR Machines. GWHP has 56 FDA-approved products, including 15 point-of-care tests. Established in 2013, the company aims to lead in the fight against various diseases, showcasing its commitment to public health.

Global WholeHealth Partners Corp. (GWHP) announced the acquisition of distribution rights for Moderna's COVID-19 vaccine, enhancing its portfolio alongside previously secured Pfizer-BioNTech and Johnson & Johnson vaccines. This strategic move positions GWHP to capitalize on the growing vaccine market, with Moderna projected to generate $19.2 billion in vaccine sales this year. The company's comprehensive suite of COVID-19 tests further strengthens its market presence. CEO Charles Strongo highlighted the efficacy of the vaccines against variants as a key competitive advantage.

Findit, Inc. (OTC PINK:FDIT) has announced that it will feature three key members who utilize its marketing campaigns to enhance their online presence. The highlighted members include Global WholeHealth Partners (GWHP), which provides medical-grade PPE and COVID-19 testing kits; ClassWorx (CHNO), a virtual instructor directory; and OTC Tip Reporter, focused on investor relations. Findit’s services aim to improve content creation, social sharing, and overall brand visibility, helping these organizations connect with a wider audience.

Global WholeHealth Partners Corp (GWHP) has acquired distribution rights for both the Pfizer-BioNTech and Johnson & Johnson COVID-19 vaccines. The Pfizer vaccine was found to be over 95% effective against severe disease from variants. This strategic acquisition enhances GWHP's capabilities in COVID-19 testing and vaccination distribution.

With a capacity to scale up to 1 million tests per day, GWHP positions itself as a significant player in the pandemic response market.

Global WholeHealth Partners Corp. (GWHP) has secured distribution rights for Johnson & Johnson's COVID-19 vaccine through Nunzia Pharmaceutical Inc., effective June 9, 2021. This strategic move positions GWHP to distribute the vaccine, leveraging its existing line of COVID-19 tests. The company aims to penetrate lower-income markets, enhancing its role in global vaccination efforts. Johnson & Johnson’s vaccine has contributed significantly to its sales, with expectations for further international expansion. GWHP currently offers a wide range of FDA-approved COVID-19 tests.

Global WholeHealth Partners Corp. (OTC: GWHP) announced its plans to provide COVID-19 testing directly to patients' homes and workplaces. By utilizing CLIA WAIVED labs for testing, including antibody and antigen tests, the company aims to facilitate faster results. Dr. Vu Le has been appointed as Medical Director to oversee these initiatives. GWHP boasts a robust portfolio with over 56 FDA-approved products and claims the capacity to deliver up to 1 million tests daily. CEO Charles Strongo emphasized the importance of rapid testing in combating the spread of COVID-19.

Global WholeHealth Partners Corp (OTC: GWHP) is enhancing its market presence through a series of strategic mergers and acquisitions. The company is set to open a new facility in the Philippines in July 2021, providing essential diagnostic products for COVID-19 and other diseases. CEO Charles Strongo highlighted the ongoing development of a groundbreaking Alzheimer's diagnostic test. GWHP aims to boost revenues through aggressive expansion, leveraging a portfolio of 56 FDA-approved products, with the capacity to increase test production significantly. The company anticipates substantial growth and improved shareholder value.

Global WholeHealth Partners Corp (OTC: GWHP) has partnered with AAJ to introduce a new line of medical products in the Philippines, including tests for COVID-19, Dengue Fever, Tuberculosis, Malaria, and Influenza A & B. This initiative is aimed at enhancing competitiveness in the region by utilizing FDA GMP products. With the Philippines facing serious health challenges, including a high incidence of TB and ongoing dengue outbreaks, these products aim to deliver critical testing solutions rapidly. Global WholeHealth claims to provide one of the largest lines of COVID-19 tests available.